Hiporhamin (Tablets) Instructions for Use

ATC Code

J05AX (Other antiviral drugs)

Clinical-Pharmacological Group

Herbal preparation with antiviral action

Pharmacotherapeutic Group

Systemic antiviral agents; direct-acting antiviral agents; other antiviral agents

Pharmacological Action

Hiporhamin is a dry purified extract from the leaves of sea buckthorn (Hippophae rhamnoides L.) of the Elaeagnaceae family, representing a polyphenolic complex of galloellagitannins, whose biologically active components are hydrolyzable tannins with common structural elements in the form of glucogalloyl and hexahydroxyphenolic residues.

Hiporhamin possesses high antiviral activity against various strains of influenza A and B viruses, adenoviruses, paramyxoviruses, herpes simplex viruses, herpes zoster, cytomegaloviruses (CMV), respiratory syncytial virus (RS virus), and human immunodeficiency viruses (HIV infection). The inhibitory effect of the drug on virus reproduction manifests at the early stages of their development. One of the mechanisms of the drug’s action is the inhibitory effect on viral neuraminidase.

Hiporhamin induces interferon production in blood cells in in vitro experiments and increases interferon levels in the blood of patients.

The drug also exhibits a moderate antimicrobial effect in in vitro experiments against gram-positive (Staphylococcus aureus) and gram-negative bacteria (Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa), tuberculous mycobacteria (Mycobacterium tuberculosis), Candida (Candida albicans), and some mycelial fungi (Microsporum canis).

Hiporhamin has low toxicity. It does not possess allergenic, immunotoxic, mutagenic, teratogenic, or carcinogenic properties.

Indications

As a therapeutic and prophylactic agent

• For influenza (A and B), parainfluenza, RS viral, adenoviral, and other acute respiratory viral infections;
• For tonsillitis occurring against the background of acute respiratory viral diseases (complex therapy);
• For acute and recurrent forms of herpes simplex of extragenital and genital localization;
• For herpes zoster, chickenpox, and CMV infection.

ICD codes

Dosage Regimen

Tablets

Treatment. Hiporhamin sublingual tablets, 1 tablet (20 mg), are held in the mouth until completely dissolved. Adults and children over 12 years are prescribed 1 tablet (20 mg) 4-6 times a day, children 6-12 years – 1 tablet (20 mg) 3-4 times a day, children 3-6 years – 1/2 tablet (10 mg) 2-4 times a day.

The duration of use ranges from 3 days to 3 weeks depending on the nosological form of the disease. For influenza – at least 3 days; for parainfluenza, RS viral, adenoviral infections, tonsillitis occurring against the background of acute respiratory viral diseases (complex therapy), and other ARVI – at least 5 days.

For chickenpox, herpes zoster, herpesvirus and CMV infections, the duration of use depends on the severity of the process and is 3-10 days for mild forms of the disease. For severe and recurrent forms of the disease, the minimum course of treatment is 2-3 weeks. Repeated courses of treatment are advisable.

For prevention during an influenza outbreak, Hiporhamin sublingual tablets are taken according to age-specific dosages from 3 days to 3 weeks.

As a prophylactic agent to prevent the development of viral complications (herpesvirus diseases and CMV infection) in the context of immunosuppressive therapy in postoperative patients, in risk groups, Hiporhamin in the form of sublingual tablets (20 mg) is used 3 times a day for 5-7 days.

Adverse Reactions

Allergic reactions are possible.

Contraindications

• Children under 3 years of age (considering the solid dosage form of the tablet);
• Sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption;
• Hypersensitivity to the drug components.

With caution diabetes mellitus.

Use in Pregnancy and Lactation

During pregnancy and breastfeeding, the use of the drug is possible if the intended benefit to the mother outweighs the potential risk to the fetus and child.

Pediatric Use

Contraindicated in children under 3 years.

Children from 2 months to 3 years are prescribed Hiporhamin lyophilisate for solutions 0.02 g in the form of an aqueous solution – nasal drops, inhalation.

Special Precautions

Hiporhamin should be prescribed as early as possible in the course of the disease. The most pronounced therapeutic effect is achieved by combining systemic and local dosage forms of the drug (rectal and/or vaginal suppositories with Hiporhamin 0.05 g (for adults); ointment for topical and external use 0.5%; Hiporhamin lyophilisate for solutions 0.02 g in the form of an aqueous solution – nasal drops, inhalation).

1 tablet of the drug contains 0.5539 g of carbohydrates, which corresponds to 0.046 XE. Patients with diabetes mellitus should take the drug after consulting a doctor.

Use in pediatrics

Children from 2 months to 3 years are prescribed Hiporhamin lyophilisate for solutions 0.02 g in the form of an aqueous solution – nasal drops, inhalation.

Effect on the ability to drive vehicles and machinery

The drug does not affect the performance of potentially hazardous activities requiring increased concentration and speed of psychomotor reactions (including driving vehicles, working with moving mechanisms).

Overdose

To date, no cases of drug overdose have been reported. With prolonged use in doses exceeding those indicated in the instructions, increased blood clotting is possible.

Treatment symptomatic.

Drug Interactions

The drug can be used in combination with other medicines (antimicrobial agents, synthetic antiviral agents, symptomatic therapy agents).

Storage Conditions

In a dry place, protected from light, at a temperature not exceeding 25°C (77°F). Keep out of reach of children.

Shelf Life

Shelf life – 4 years.

Dispensing Status

Over-the-counter.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.